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Abstract: Russell’s viper bites are potentially fatal from severe bleeding, renal failure and capillary
leakage. Snake venom metalloproteinases (SVMPs) are attributed to these effects. In addition
to specific antivenom therapy, endogenous inhibitors from snakes are of interest in studies of
new treatment modalities for neutralization of the effect of toxins. Two major snake venom
metalloproteinases (SVMPs): RVV-X and Daborhagin were purified from Myanmar Russell’s
viper venom using a new purification strategy. Using the Next Generation Sequencing (NGS)
approach to explore the Myanmar RV venom gland transcriptome, mRNAs of novel tripeptide
SVMP inhibitors (SVMPIs) were discovered. Two novel endogenous tripeptides, pERW and
pEKW were identified and isolated from the crude venom. Both purified SVMPs showed
caseinolytic activity. Additionally, RVV-X displayed specific proteolytic activity towards gelatin and
Daborhagin showed potent fibrinogenolytic activity. These activities were inhibited by metal chelators.
Notably, the synthetic peptide inhibitors, pERW and pEKW, completely inhibit the gelatinolytic and
fibrinogenolytic activities of respective SVMPs at 5 mM concentration. These complete inhibitory
effects suggest that these tripeptides deserve further study for development of a therapeutic candidate
for Russell’s viper envenomation.
Keywords: snake venom metalloproteinases; snake venom metalloproteinase inhibitors; Russell’s
viper; viper venom
1. Introduction
Russell’s viper (Daboia russelii) is a medically important snake, variants of which are distributed
throughout East and Southeast Asia. A Russell’s viper bite has a 60% morbidity rate and the fatality
rate is 8.2% in Myanmar [1]. The cause of death includes shock, massive bleeding and renal
failure. Snake venom metalloproteinases (SVMPs) play a major role in the local and systemic
clinical manifestations: blistering, necrosis and bleeding from the fang marks and incoagulable blood,
thrombocytopenia, spontaneous systemic bleeding, hypotension, increased permeability and reduced
urine output [2]. Although Russell’s viper antivenoms are available, their efficacy in reversal tissue
damage, such as acute renal failure, is limited [3]. Novel treatment modalities are required.
Snake venom metalloproteinases (SVMPs) play major roles in pathogenesis of Russell’s viper
bites [4,5]. SVMPs are categorised into P-I to P-III classes according to their domain organization with
different molecular weights [6]: Class I (P-I) contains only a prodomain and a metalloproteinase domain
(20–30 kDa); Class II (P-II) contains a prodomain, metalloproteinase domain followed by disintegrin
domain (30–60 kDa); Class III (P-III) contains a pro, metalloproteinase, disintegrin-like and cysteine-rich
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domain (60–100 kDa). There are subclasses in P-II and P-III depending on post-translational
modifications. The variation in domain composition between SVMP classes contributes to a wide
spectrum of substrate specific proteolytic activity. The active site of the metalloproteinase domain
has a consensus H142EXXHXXGXXH152 sequence. The catalytic zinc-ion is located at the bottom of
the active-site cleft, and tetrahedrally coordinated by His142, His146, His152, and a water molecule
anchored to Glu143 [7]. The degradation of endothelial cell membrane proteins (integrin and cadherin),
basement membrane components (fibronectin, laminin and collagen) and blood coagulation proteins
(fibrinogen, factor X and prothrombin) leads to haemorrhage. Generally, P-III SVMPs have more potent
haemorrhagic activity than P-I and P-II SVMPs [8].
In order to protect against auto-digestion by SVMPs, snake venom of several species are found
to contain natural protease inhibitors: citrate and small peptides. The latter bind selectively to
SVMPs in the venom glands to protect glandular tissues and venom factors from self-digestion
by SVMPs [9]. Three endogenous peptides: pyroGlu-Lys-Trp (pEKW), pyroGlu-Asn-Trp (pENW) and
pyroGlu-Gln-Trp (pEQW) isolated from venom of Taiwan habu (Trimeresurus mucrosquamatus) showed
an inhibitory action on proteolytic activity of metalloproteinases present in the crude venom [10].
It is reported that these peptide inhibitors regulate the proteolytic activities of their SVMPs in
a reversible manner under physiological conditions [11]. Other pit vipers, such as Bothrops asper [12]
and some rattlesnakes [13], also have venoms containing endogenous tripeptides: pEQW and pENW.
African vipers, Echis ocellatus and Cerastes cerastes cerastes, have pEKW tripeptides. These tripeptides
are encoded by tandemly repeating elements from the transcripts which also contain a CNP (C-type
natriuretic peptide) homologous sequence at the C-terminus [14]. Two peptides: PtA (pENW) and
PtB (pEQW) isolated from venom liquor of Deinagkistrodon acutus (Hundred-pacer viper) showed
anti-human platelet aggregation activity in vitro and protection effects on ADP-induced paralysis and
formation of pulmonary thrombosis in mice [15].
We hypothesized that Myanmar Russell’s viper venom might contain endogenous peptides
to neutralise its own potent SVMPs. The goal of this research was to purify and identify specific
SVMP inhibitors (SVMPIs) from the venom as well as from venom glands and to determine their
inhibitory action on purified SVMPs from same source of venom. From the transcriptome of the snake,
novel SVMPI transcripts containing tripeptide motifs and ANP (atrial natriuretic peptide) sequences
were found. Two tripeptides were purified from the venom and identified as pERW and pEKW.
Their effect on biological activities of two SVMPs: RVV-X and Daborhagin from the same venom,
purified through newly developed strategy, were examined. Both synthetic peptides showed complete
inhibitory action on the gelatinolytic activity of RVV-X and fibrinogenolytic activity of Daborhagin
at 5 mM concentration (approximate protease to inhibitor molar ratio of 1:500). The results might
contribute to the development of complementary candidates for current antivenom therapy of Russell’s
viper bites, as well as for novel therapeutic agents for cardiovascular diseases.
2. Results
2.1. Purification and Identification of SVMPs from Myanmar Russell’s Viper Venom
2.1.1. Purification of SVMPs
The crude venom of Myanmar Russell’s viper (MRV) was initially separated on a Superdex
200 column. Of the three major protein-containing peaks, only the first possessed caseinolytic activity
(Figure 1). These fractions were pooled and further purified on a Resource Q anion-exchange
column. The proteins resolved into two peaks and the first peak (Q1) exhibited caseinolytic activity
(Figure 2a). The purity of proteins in Q1 was determined on both reducing and non-reducing
SDS-PAGE. Non-reducing SDS-PAGE of this fraction showed it to contain two bands at 85 kDa
and 67 kDa. Under reducing conditions, the main protein bands ran at approximately 67 kDa band
and low molecular weight (15–20 kDa) bands were evident.










Figure  2.  Separation  of  fractions  15–18  from GFC  on  a  Resource Q  anion‐exchange  column  (a) 
Chromatography  trace  showing  protein  concentration  and  caseinolytic  activity.  Peak  one  (Q1) 
contained  fractions  with  protease  activity;  SDS‐PAGE  of  the  purified  proteins  under  (b)  non‐
reducing; and (c) reducing conditions. 
Figure 1. Fractionation of Myanmar Russell’s viper crude venom through Superdex 200 gel filtration
column (5 × 160 cm). Crude ve s separated in .01 M phosphate buffered saline (pH 7.4) at
2 mL/min. Each fraction lu e. The blue continuous line shows the protein o centration










Figure  2.  Separation  of  fractions  15–18  from GFC  on  a  Resource Q  anion‐exchange  column  (a) 
Chromatography  trace  showing  protein  concentration  and  caseinolytic  activity.  Peak  one  (Q1) 
contained  fractions  with  protease  activity;  SDS‐PAGE  of  the  purified  proteins  under  (b)  non‐
reducing; and (c) reducing conditions. 
Figure 2. Separation of fractions 15–18 from GFC on a Resource Q anion-exchange column
(a) Chromatography trace showing protein concentration and caseinolytic activity. Peak one (Q1)
contained fractions with protease activity; SDS-PAGE of the purified proteins under (b) non-reducing;
and (c) reducing conditions.
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This material (Q1) was then subjected to further separation on either HIC for activity studies,
or RP-HPLC when proteins were prepared for mass spectrometry. A Phenyl Superose column was
used for HIC during which the protein fraction resolved into 2 peaks: H1 (eluted at 13 min), and H2
(eluted at 29 min), respectively (Figure 3a–c). For RP-HPLC, a Phenomenex Luna C4 column was used
and again the proteins were separated into 2 peaks (R1 and R2) (Figure 3d–f). SDS-PAGE analysis
and activity studies showed H1 to be the same protein as R1 running at 85 kDa under non-reducing
conditions, but at 67 kDa with several subunits at 15–20 kDa when reduced. H2 is the same as R2,
with a single band at 68 kDa under both reducing and non-reducing conditions.
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Figure 3. (a) Chromatography of fraction Q1 from the Resource Q column on Phenyl Superose column
(HIC) showing protein-containing peaks (H1 and H2); (b) non-reducing; and (c) reducing SDS-PAGE
of purified proteins (silver-stained); (d) Chromatography of fraction Q1 from Resource Q column on
a C4 RP-HPLC column; Two protein peaks were observed: R1 and R2; SDS-PAGE of purified proteins
R1 and R2 (e) under non-reducing conditions; and (f) reducing conditions.
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2.1.2. Identification of SVMPs
Both proteins with protease activity were purified by C4 RP-HPLC in preparation for mass
spectrometric analysis (see R1 and R2 in Figure 3d). For R1, the protein was reduced and treated with
iodoacetamide and digested with trypsin in the presence of 2 M urea and the digest was analysed
using LC-ESI-MS/MS (Figure 4). LC-ESI-MS/MS analysis of the tryptic peptides provided sufficient
sequence coverage to match to the mature sequence (residues 189–615) of the Eastern Russell’s viper
(Daboia russelii siamensis) RVV-X H chain VM3CX_DABSI (Q7LZ61) (Figure 4). In the same digest
mixture we also found matches to RVV-X light chain proteins LC1 SLLC1_DABSI (Q4PRD1) and LC2



























Figure 4. Data from LC-ESI-MS/MS analysis of the tryptic peptides from purified RVV-X. The data was
obtained by digesting the R1 fraction from RP-HPLC with trypsin. The prepro-sequence of RVV-X H
chain (VM3CX_DABSI; Q7LZ61) annotated to show the peptides (underlined) identified in this analysis.
All matched peptides were found within the sequence of the processed protein (residues 189–615).
The protein R2 from RP-HPLC was digested in the same way as R1. In this case MALDI-MS
analysis was used to identify tryptic peptides hat matched the mass [M + H+] of those predicted
from the sequence of Daborhagin-K (Indian Russell’s viper) (VM3DK_DABRR) (B8K1W0) (Figure 5).
T majority of the m st bundant peptides matched the mass of expected tryptic peptides and notably
we f und many of the same tryptic peptides as did Chen et al. (Table 2 in ref. [16]) for Daborhagin-M.
As a result of this work we can identify R1, H1 as the Myanmar Russell’s viper RVV-X and R2,
H2 as Myanmar Russell’s viper Daborhagin and will to refer them as such from hereon.














addition  to a QKW motif was  found  in  the MRV  transcripts. The tripeptides were  flanked by  the 
conserved PXXQ(K/R)WXXP motifs. The SVMPI transcripts of MRV also contained a conserved poly‐
Gly  (pG) motif  instead  of  the  poly‐His  poly‐Gly  (pHpG)  seen  in  E.  ocellatus  SVMPI  transcripts. 
Moreover, the C‐terminal portion of the SVMPI transcripts of MRV have an atrial natriuretic peptide 
(ANP) domain  in place of  the C‐type natriuretic peptide  (CNP) domain  in  the  two African viper 
SVMPI transcripts (Figure 6). 
   
Figure 5. MALDI-MS spectrum of tryptic peptides from purified Daborhagin. The data w s obtained by
digesting the R2 fraction from RP-HPLC with trypsin. The numb rs abov the peptides masses indicates
the residue numbers for the p ptides matched o the sequence of Daborhagin K (VM3DK_DABRR)
(B8K1W0). All m/z values are for the M + H+ ions. The ions at 1854 and greater have been labeled wi h
t e m/z value for the ion containing one carbon as the C13 is tope.
2.2. Analysis of SV PI Transcripts from Myanmar Russell’s Viper Transcriptome
Fro the transcripto e of yan ar Russell’s viper veno glands, a total of 4 contigs were
annotated as the Snake Venom Metalloproteinase Inhibitors (SVMPI). The conceptually translated
proteins ere aligned with those transcripts of African vipers, Echis ocellatus (A8YPR6) and
Cerastes cerastes cerastes (A8YPR9). The signal peptides are highly similar and a new tripeptide QRW
motif in addition to a QKW motif was found in the MRV transcripts. The tripeptides were flanked by
the conserved PXXQ(K/R)WXXP motifs. The SVMPI transcripts of MRV also contained a conserved
poly-Gly (pG) motif instead of the poly-His poly-Gly (pHpG) seen in E. ocellatus SV PI transcripts.
oreover, the C-terminal portion of the SV PI transcripts of RV have an atrial natriuretic peptide
(ANP) domain in place of the C-type natriuretic peptide (CNP) domain in the two African viper SVMPI
transcripts (Figure 6).
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mass of pEKW  is  443.2). Analysis of peak Bp,  also  showed  a  strong M  + H+  ion  at m/z  472.2(the 
predicted monoisotopic mass  of pEKW  is  471.2)  (Figure  8). MS/MS  analysis  of  these  tripeptides 
produced a set of fragment ions consistent with their expected amino acid sequence (data not shown). 
   
Figure 6. lti le seq ence align ent of the polypepti e encode by yan ar Russell’s viper
SV PI transcripts ( RV1-4) with those of two African vipers [C. c. cerastes (A8YPR9) and E. ocellatus
(A8YPR6)]. The signal peptides are denoted by a solid line. The active tripeptides are underlined and
identified with three asterisks. The varied residue is identified by a single asterisk. The CNP do ains
are indicated with a solid arrowed line and ANP domains with a dashed arrowed line.
2.3. Purification and Identification of Tripeptides
The molecular fractions from Sup rdex 200 chr m tography were analysed using
C18 RP-HPLC. Fraction 48 was found to contain the highest conc ntration of the tripeptides.
Upon RP-HPLC analysis of this fraction, two eaks (Ap and Bp) eluted close together at 31–33 min
(Figure 7). Th se p aks possessed th same elution time as that of two synthetic peptides pEK
(peak As and pERW (peak Bs), respectively. RP-HPLC analysis of mixtures of na ural an ynthetic
tripeptides sh wed perfect co-chromatography. The purifie endogenous tripeptide were then
analysed using ESI-MS. The resultant spectra of peak Ap showed a strong M + H+ ion at m/z 444.2,
(the predicted monoisotopic m ss of pEKW is 443.2). Analysis of peak Bp, also showed strong M + H+
ion at m/z 472.2(the predicted monoisotopic mass of pEKW is 471.2) (Figure 8). MS/MS analysis of
these tripeptides produc d a set of fragment ons consisten with their expected amino acid sequence
(data not shown).
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i 7. C18 RP-HPLC analysi of synthetic tripeptides, pEKW and pERW (1 µg of each) (upper panel);
and fraction 48 (200 µL) (lower panel) obtained from gel filtration chromatography of crude venom.
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included  in  the  assay  to  test  the  specificity  of  amino  acid  residue  in  the  second  position  of  the 
tripeptides. 
   
Figure 9. Gelatinolytic activity of RVV-X and Daborhagin on 0.25% gelatin zymogram after
48 h-incubation at 37 ◦C. Dab: Daborhagin; Ctrl: combined sample of two purified proteins.
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Figure  10.  Fibrinogenolytic  activity  of  RVV‐X  and Daborhagin.  10  μg/mL  purified  enzyme was 
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Figure 10. Fibrinogenolytic activity of RVV-X and Daborhagin. 10 µg/mL purified enzyme
was incubated with 1 mg/mL fibrinogen solution at 0, 15, 60, 120 min and 20 h-incubation.
Sample: (a) RVV-X; (b) Daborhagin. Ctrl: fibrinogen control; STD: molecular weight markers.
2.5. Inhibitory Assay with Synthetic Tripeptides
2.5.1. Effect of Synthetic Tripeptides on the Gelatinolytic Activity of RVV-X
The gelatinolytic a tivity of RVV-X was completely inhib ted by both synthetic tripeptides pEKW
and pERW at 5 mM concentration when incubated with 1 mg/mL gelatin solution at 37 ◦C (Figure 11).
The α-chains (100 kDa & 130 kDa), β-chain (200 kDa) and γ-chain (300 kDa) of gelatin were totally
degraded by RVV-X in a 20 h-incubation, whereas these gelatin subunits were still intact in samples
containing tripeptides or EDTA after 20 h of incubation. The tripeptide pEEW was included in the assay
to test the specificity of amino acid residue in the second position of the tripeptides.
























of  its bites  reflect  the high content of proteases  such as  snake venom  serine proteases and snake 
venom metalloproteinases (SVMPs). It has been shown that the SVMPs comprise approximately 11% 
to  65%  of  the  total  protein  in  the  Viperidae  venoms  [17].  In Myanmar  Russell’s  viper,  SVMPs 
Figure 11. Gelatinolytic activity of RVV-X. Gelatin (1 mg/mL) was incubated with 10 µg/mL RVV-X
for 1 h and 20 h at 37 ◦C, either with or without EDTA or synthetic tripeptides: pERW, pEKW, pEEW.
Control = reduced gelatin, STD = molecular weight markers.
2.5.2. Effect of Synthetic Tripeptides on the Fibrinogenolytic Activity of Daborhagin
The fibrinogenolytic activity of Daborhagin was completely inhibited by both synthetic tripeptides
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f  its bites  reflect  the high content of proteases  such as  snake venom  serine proteases and snake 
venom metalloprote n ses (SVMPs). It ha been sh wn that the SVMPs comprise approximately 11% 
to  65%  of  the  to al  protein  in  the  Viperidae  venoms  [17].  In Myanmar  Russell’s  viper,  SVMPs 
Figure 12. Fibrinogenolytic activity of Daborhagin. Fibrinogen (1 mg/mL) was incubated with
10 µg/mL Daborhagin for 1 h and 20 h at 37 ◦C with or without EDTA or synthetic tripeptides: pERW,
pEKW, pEEW. Control = reduced fibrinogen, STD = molecular weight markers.
3. Discussion
In the current study, we have developed a new method which can be used to simultaneously
isolate the two SVMPs, RVV-X and Daborhagin, from Myanmar Russell’s viper venom. The relative
amounts of these enzymes in the venom were determined. In addition, four novel RNA sequences
of SVMP inhibitor (MRV1-4) were derived from the venom gland transcriptome. These sequences
are different from those of previously reports in other snakes. For the first time in studies of Russell’s
viper venom, two tripeptide SVMP inhibitors, pERW and pEKW have been isolated. Evidence for
the complete inhibition of RVV-X and Daborhagin activities by these tripeptides is presented to support
our hypothesis.
Russell’s viper is a venomous species of the South-East Asian region. The clinical manifestations
of its bites reflect the high content of proteases such as snake venom serine proteases and snake venom
metalloproteinases (SVMPs). It has been shown that the SVMPs comprise approximately 11% to 65% of
the total protein in the Viperidae venoms [17]. In Myanmar Russell’s viper, SVMPs contribute to
20% of the crude venom (data not shown) and Class III SVMPs are found to be the major component.
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In comparison with other species, the Myanmar species have 6–7 times more Daborhagin than Indian
species [16] and SVMPs, mainly RVV-X, in Sri Lankan species comprise just 6.9% of the crude
venom [18]. Thus, it can be noted that the Myanmar venom contains greater amounts of SVMPs
than that of the Indian and Sri Lankan species. The variations in types and amounts of SVMPs in
venom among different subspecies of Russell’s viper might be due to diversity in their prey at different
locations and this could lead to the dissimilar severity or clinical presentations of snakebite patients.
Russell’s viper venom factor X activator (RVV-X) is a well-characterised Class III metalloproteinase
(formally known as Class IV) which specifically activates coagulation factor X by hydrolysis of
an Arg-Ile bond in factor X. It is a glycoprotein consisting of a heavy chain (α-chain, 57.6 kDa) and
two light chains (β- and γ-chains, 19.4 kDa and 16.4 kDa) linked by disulfide bonds [19]. In addition
to proteolytic activity on factor X and IX, RVV-X also inhibits collagen- and ADP-stimulated platelet
aggregation [20] and has a strong affinity for protein S [21]. Factor X activators are also found in
Vipera lebetina (blunt-nosed viper) in which it exhibits specific proteolytic activity towards human
factor X and also factor IX, but it is not active against prothrombin nor fibrinogen [22].
In the present study, the purified RVV-X was shown to be composed of a heavy chain (67 kDa)
and two light chains (20 kDa and 15 kDa). The two thin bands on SDS-PAGE at around 15 kDa
level suggested that the γ-light chain in Myanmar species might exist as 2 forms, likely due to either
amino acid variation or differences in N-glycosylation. Our experiments showed that MRV RVV-X
possesses hydrolytic activity to gelatin (Type I collagen, bovine), which had not been characterised
before for RVV-X.
Another potent Class III SVMP, Daborhagin, composed of metalloproteinase, disintegrin and
cysteine-rich domains, was also purified from MRV venom. The Daborhagin-M from Myanmar
Russell’s viper venom specifically digested the α-chain of fibrinogen, fibronectin and type IV collagen
in vitro and exhibited haemorrhagic [16], edema inducing and myonecrotic activity in mice [23].
In our studies, a 67 kDa metalloproteinase was isolated and matched to Daborhagin-K from Indian
species using mass spectrometric analysis of tryptic peptides. This MRV Daborhagin exhibited potent
α-fibrinogenolytic activity, but did not digest gelatin.
In the current purification strategy, the two SVMPs were co-purified initially, but then could
be separated from each other using either hydrophobic interaction chromatography or RP-HPLC.
Better resolution was evident on RP-HPLC, and the presence of multiple forms of RVV-X was indicated
by the irregularity of the RVV-X RP-HPLC peak, suggesting heterogeneity of the protein (R1, Figure 3d).
Two isoforms of the heavy chain and 6 isoforms of the light chain from RVV-X have been revealed on
2-D electrophoresis in the proteomic study of Risch, M et al. in the same species [24].
New SVMPI transcripts from Myanmar Russell’s viper were discovered containing novel
two inhibitory tripeptides, QKW and QRW. The tripeptide sequences are found in the same transcript
as natriuretic peptide sequences, as is the case in African vipers. This assortment of different peptide
sequences in the same transcript could be related to independent evolution of toxin genes in snakes.
The conserved proline residues in the consensus sequence PXXQ(K/R)WXXP might be a signal point
for cleavage of tripeptides from transcripts. The mechanism for release of tripeptides from their
transcripts is still unknown. These tripeptides and natriuretic peptides are observed separately in
venom, although they are encoded from the same transcript. Since ANP is homologous to hormone,
it might be processed near the effective cells. The release and modification of tripeptides [25] might
probably occur during the exocytosis process at an earlier stage than the natriuretic peptides [26].
The aforementioned inhibitory tripeptides were purified from the MRV venom as their
pyroglutamate forms, pEKW and pERW. These were identified using RP-HPLC (co-chromatography
with synthetic peptides), LC-ESI-MS analysis of intact mass and LC-ESI-MS/MS sequencing.
Although the tripeptide pEKW purified from MRV venom has been found in other snake species,
such as Trimeresurus mucrosquamatus [10], Echis ocellatus, and Cerastes cerastes cerastes [14], the tripeptide
pERW purified here has not been found in the venom of any other snake species.
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The synthetic tripeptides pERW, pEKW and pEEW showed complete inhibition of the gelatinolytic
activity of RVV-X and of the fibrinogenolytic activity of Daborhagin at 5 mM concentration of each
inhibitor. Non-selective inhibition of all three synthetic peptides on biological activities of SVMPs
reflects the importance of the first pyroGlu and the final tryptophan residue in the blocking mechanism
at the active site of SVMP. The crystal structure of TM-3 (a SVMP from Trimeresurus mucrosquamatus)
bound to tripeptide inhibitors (a proteinase and inhibitors model from Taiwan habu) revealed that
the inhibitor Trp residue deeply inserts into the S-1 pocket of the protease and provides a greater
inhibition than other smaller amino acids. Similarly, the pyro-ring of the inhibitor is required for fitting
into the S-3 position of the protease and the activity of inhibitor becomes weaker in the absence of
pyro-ring. The native middle residue is also position-specific to the S-2 site [11]. Tripeptides from
different species share same first (pyroGlu-) and third (tryptophan) residues. The variability of
the middle residue may be dependent on species variation of the SVMPs.
4. Conclusions
In summary, we have isolated and identified two major SVMPs and two endogenous tripeptides
from Myanmar Russell’s viper venom. The two synthetic tripeptides showed specific inhibition
against the fibrinogenolytic and gelatinolytic activities of the SVMPs. These findings may provide
a means to explore potential drug design in using these tripeptide inhibitors, or analogues of theses as
alternative or additional tools in treating the toxic effects of envenomation, as well as in thrombosis
and related diseases.
5. Materials and Methods
5.1. Venoms and Venom Glands
Lyophilised crude venom was obtained from No. 1, Myanmar Pharmaceutical Factory,
Yangon, Myanmar. The salivary glands from Myanmar Russell’s viper (Daboia russelii siamensis)
were dissected in the Snake Farm, MPF, Yangon, Myanmar and used for RNA-Seq
(RNA sequencing). The experimental plan was approved by the Animal Care and Use Committee,
Chulalongkorn University (CU-ACUC) (No. 17/2558). Synthetic tripeptides (98% purity) were
purchased from Severn Biotech Ltd., Worcestershire, UK and supplied with data from MS analysis to
confirm their masses to be within 0.4% of the predicted values.
5.2. Transcripts Analysis of SVMPIs
Next-generation sequencing of mRNA from Myanmar Russell’s viper (2 adult males and 2 adult
females) venom glands was performed on an Illumina HiSeq2000 platform. De novo assembly was
performed using Trinity (r20140717). Annotation of SVMPI transcripts were archived through Blastn
searches against the collected NCBI nucleotide database with search words “venom” and “serpents”.
The annotations with a high score at the top hit list were picked up.
The SVMPI transcripts were further analysed with Blastx and ORF finder for final best annotation
and identification of the full-length transcript. The alignment of translated SVMPI sequences with those
from other snakes were performed by using Clustal Omega followed by shading with BOXSHADE
3.21 (K. Hofmann, Koeln, Germany & M. Baron, Surrey, UK).
5.3. Protein Concentration
Protein concentration was determined by using Bradford reagent (BioRad, Hemel Hempstead,
UK). The absorbance was measured at 595 nm and the calibration curve was prepared with a bovine
gamma globulin standard (0–1.5 mg/mL).
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5.4. Purification of SVMPs
All chromatographic procedures were performed on either a Bio-Cad Vision Workstation (GFC)
or a GE Healthcare AKTA System (anion-exchange, HIC and RP-HPLC).
5.4.1. Gel Filtration Chromatography (GFC)
Crude venom (100 mg) dissolved in 5 mL of 0.01 M phosphate buffered saline (pH 7.4) was
applied to a Superdex 200 column (5 × 160 cm) pre-equilibrated with the same buffer. Elution was
carried out with the same buffer. The flow rate was 2 mL/min and 6 mL fractions were collected.
The fractions having metalloproteinase activity (fractions 15–18) were combined for further purification.
The fractions eluting near the total volume were analysed for tripeptides using RP-HPLC with
subsequent MS analysis.
5.4.2. Anion-Exchange Chromatography
The SVMP-containing sample obtained from GFC was applied to a Resource Q anion-exchange
column (6 mL) pre-equilibrated with 0.05 M Tris-Cl buffer (pH 8.0). Elution was achieved with a linear
NaCl gradient from 0 to 0.5 M in the same buffer at a flow rate of 0.6 mL/min and 1.8 mL fractions
were collected. Elution was monitored at 280 nm.
5.4.3. Hydrophobic Interaction Chromatography (HIC)
To further purify the SVMPs for activity measurements, fractions from Resource Q were loaded
onto a Phenyl Superose column (1 mL) equilibrated in 2.5 M NaCl, 50 mM Tris-Cl, pH 7.8. Samples in
Tris-Cl were adjusted to 2.5 M in NaCl and were centrifuged at 10,000× g for 5 min before loading
onto the column. Separation was achieved by a 30 min-gradient of 2.5–0 M NaCl in 50 mM Tris-Cl,
pH 7.0, using a flow rate of 0.25 mL/min. Elution was monitored at 280 nm and 0.25 mL fractions
were collected.
5.4.4. Reversed Phase High Performance Liquid Chromatography (RP-HPLC)
For MS analysis, SVMPs were purified using RP-HPLC rather than HIC. Fractions from Resource
Q chromatography were made up to 0.2% (v/v) in TFA, centrifuged at 10,000× g for 5 min and then
applied to Phenomenex Aeris C4 column (150 × 2.1 mm, 5 micron). The proteins were separated in
a two-part acetonitrile gradient in 0.08% TFA: 0%–40% over 25 min then 40%–65% over 5 min and
elution was monitored at 280 nm. The flow rate was 0.15 mL/min and 0.25 mL fractions were collected.
5.5. Purification of Tripeptides
Fractions from GFC suspected to contain small molecular weight components were made up to
0.2% (v/v) in TFA, centrifuged at 10,000× g for 5 min and applied to Phenomenex Luna C18 RP-HPLC
column (100 × 2.1 mm) equilibrated in 0.08% TFA. The components were separated at 0.15 mL/min
with a three-part acetonitrile gradient in 0.08% TFA: 0%–12% over 5 min, 12%–28% over 50 min and
then 28%–65% over 10 min. Elution was monitored at 280 nm.
5.6. Mass Spectrometric Analyses
Putative RVV-X (10 µg of R1 from RP-HPLC) was reduced, treated with iodoacetamide and
digested with 1.0 µg trypsin in the presence of 2 M urea. The resulting peptides were analysed by
LC-ESI-MS/MS using an Acquity UPLC CSH Peptide C18 RP column (Waters, Milford, MA, USA)
connected to a Q-Exactive (ThermoFisher, Northumberland, UK) MS instrument. Peaks Studio 8.0
(BSI, Waterloo, Canada) was used to analyse the resulting MS/MS data against the sequences for
Eastern Russell’s viper RVV-X H chain VM3CX_DABSI (Q7LZ61) and light chains LC1 SLLC1_DABSI
(Q4PRD1) and LC2 SLLC2_DABSI (Q4PRD2).
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Putative Daborhagin (5 µg of R2 from RP-HPLC) was reduced, treated with iodoacetamide and
digested with 0.5 µg trypsin in the presence of 2 M urea. The resulting peptides were desalted and mass
spectrometric analysis was performed using a MALDI-TOF instrument (Waters-Micromass, Milford,
MA, USA). Samples were analysed by mixing a 1 µL solution of the tryptic peptides with an equal
volume of 5.7 mg/mL α-cyano-4-hydroxycinnamic acid in 60% acetonitrile/0.1% trifluoroacetic acid
and laying this onto a dried bed of 1 µL of 25 mg/mL α-cyano-4-hydroxycinnamic acid. Laser energy
was set at 25% and detector voltage 1800 V. Ion spectra were collected in the mass range of 1000–3000 Da.
Data analysis was performed using MassLynx (Waters, Milford, MA, USA). The tryptic peptide
masses obtained were matched manually with those predicted (using ExPASy Peptide Mass) of
a sequence for Daborhagin-K (VM3DK_DABRR; B8K1W0) retrieved from UniprotKB [27] using search
word ‘Daborhagin’.
The purified tripeptides were analysed by ESI-MS and ESI-MS/MS using the same instrument
and conditions as used to analyse the tryptic peptides from RVV-X.
5.7. Analysis by SDS-PAGE
Protein purity was determined by SDS-PAGE [28] on a 12% or 15% resolving gel and 4% stacking
gel using a Mini-PROTEAN 3 electrophoresis system (BioRad, Hemel Hemstead, UK). Samples were
loaded in either reduced or non-reduced form. Gels were run at 200 V, 30 mA per gel, for 50 min.
Proteins were visualised with Coomassie Brilliant Blue R250 V followed by destaining with methanol:
water: acetic acid (30:60:10). Alternatively, proteins were visualised by silver staining as performed by
method of Heukeshoven & Dernick [29].
5.8. Caseinolytic Activity
The proteolytic activity was estimated by hydrolysis of heated casein using the Anson method [30].
The reaction mixture, consisting of 500 µL casein (20 mg/mL) in 0.1 M Tris-Cl (pH 8.0), 20 µL venom
was incubated for 30 min at 37 ◦C. The reaction was quenched by the addition of 500 µL of
5% trichloroacetic acid (TCA) at room temperature. After centrifugation at 10,000× g for 5 min,
the hydrolysed substrate un-precipitated with TCA was determined by Folin Ciocalteau method [31].
Thus, 400 µL of the supernatant was mixed with 1 mL of 0.5M Na2CO3 and 200 µL of diluted (1:5) Folin
& Ciocalteau’s phenol reagent. The mixture was then incubated at 37 ◦C for 30 min and the absorbance
was measured at 660 nm. One enzyme unit is defined as the amount of enzyme which hydrolyses
casein to produce color equivalent to 1.0 µmole of tyrosine per minute at pH 8.0 at 37 ◦C.
5.9. Gelatinolytic Activity
The gelatinolytic activity of the purified enzyme was analysed by zymography [32]. The purified
metalloproteinase was diluted in SDS sample buffer under non-reducing conditions and run on 10%
SDS-polyacrylamide gels (0.75 mm) co-polymerised with 0.5 mg/mL of gelatin. After electrophoresis,
the gels were washed in 2.5% Triton X-100 for 30 min and then washed three times in distilled
water to remove any Triton. Gels were then incubated in developing buffer (50 mM Tris-Cl, pH 7.8,
200 mM NaCl, 5 mM CaCl2, 0.02% Brij 35) for 18 h at 37 ◦C. The gels were stained with 0.5% Coomassie
blue R-250 in methanol: acetic acid: water (5:10:85) solution and subsequently destained in methanol:
acetic acid: water (10:5:85). The presence of gelatinolytic activity was defined as clear bands on the dark
blue background.
5.10. Fibrinogenolytic Activity
The fibrinogenolytic activity was assayed by SDS-PAGE (4% stacking/12% resolving gel) as
described by Ouyang & Teng [33]. Equal volumes of fibrinogen (1 mg/mL in 0.05 M Tris-Cl, pH 8.5)
and 20 µg/mL of enzyme were incubated at 37 ◦C for various times intervals. At 0, 5, 15, 30, 60 and
120 min, 200 µL of the incubated solution was mixed with 400 µL of denaturing buffer containing
0.2 M Tris-Cl (pH6.8), 20% glycerol, 10% sodium dodecyl sulfate (SDS), 0.05% bromophenol blue and
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10 mM β-mercaptoethanol and heated at 100 ◦C for 10 min to stop the digestion. Proteolytic activity
was determined on the Coomassie blue-stained gel after electrophoresis by observing the cleavage
patterns of purified fibrinogen chains.
5.11. Inhibition of Gelatinolytic Activity
The effect of synthetic tripeptides and EDTA on purified protein was assayed using SDS-PAGE
(4% stacking/10% resolving gel) to determine gelatin degradation. The purified protein (10 ng/µL) was
incubated firstly with synthetic tripeptide (5 mM) or EDTA (100 µM) at 37 ◦C for 10 min. Then, 10 µL
of gelatin solution (2 mg/mL in distilled water) was added and 20 µL of this incubated solution
was taken out at 1 h and 20 h, mixed with 5 µL of 5× denaturing buffer and heated at 95 ◦C for
2 min. The cleavage patterns on gelatin by the enzyme was observed on Coomassie blue-stained gels
after electrophoresis.
5.12. Inhibition of Fibrinogenolytic Activity
The effect of synthetic tripeptides or EDTA on purified protein was assayed using SDS-PAGE
(4% stacking/12% resolving gel) to determine fibrinogen degradation. The purified protein (32 ng/µL)
was incubated firstly with synthetic tripeptide (5 mM) or EDTA (100 µM) at 37 ◦C for 10 min.
Then, 10 µL of fibrinogen solution (2 mg/mL in distilled water) was added and 20 µL of this incubated
solution was taken out at 1 h and 20 h, mixed with 5 µL of 5× denaturing buffer and heated at
95 ◦C for 2 min. The cleavage effect on fibrinogen chains by the SVMPs were observed on Coomassie
blue-stained gel following electrophoresis.
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